GeneQuine develops gene therapy-based drugs for the treatment of osteoarthritis. The goal is the development of a gene therapy drug for osteoarthritis in humans. However, GeneQuine focuses initially on gaining market authorization for its drug candidates for horses and dogs, because obtaining regulatory approval for veterinary drugs is significantly less costly and markedly faster compared with human medicines.
Kilian Guse, PhD
Dr. Guse has more than 10 years experience in the field of gene therapy and is author of more than 30 scientific publications in international, peer-reviewed journals and book chapters on this topic.
Stanislav Plutizki, PhD
Vice President Regulatory and Medical Affairs, Co-Founder
Prior to co-founding and working for GeneQuine, Dr. Plutizki was international medical manager at the regulatory and global medical marketing department at Berlin Chemie AG (Menarini Group), Berlin, Germany.
Michael Wallmeyer, PhD
Cornell University is an Ivy League research university located in Ithaca, New York, USA.
Baylor College of Medicine
Baylor College of Medicine (BCM), located in Houston, Texas, USA is one of the leading medical schools and biomedical research institutes in the country.